UK Revokes Marketing Authorization for IXCHIQ®; Valneva Continues Brazil Trials

The Medicines and Healthcare products Regulatory Agency revoked the UK marketing authorization for IXCHIQ® following a benefit-risk assessment of the vaccine for travelers. This decision was based on a review of previous safety data and did not identify any new safety signals. The product licenses for IXCHIQ® remain valid in the EU, Canada, and Brazil.

Valneva expects minimal impact on its overall sales revenue due to the revocation, as the product was not actively distributed in the UK. The company continues its pilot vaccination strategy in Brazil, where over 61,000 people have been vaccinated without new safety concerns.